Investigational drug · Phase 3
ADC189
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza Type A, Influenza Type B.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "ADC189"
First trial start
2024
Aug 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADC189", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza Type A
- Influenza Type B
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ADC189" as an intervention, largest first.
- ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus InfectionPivotal-lookingCompleted
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06342921 · 749 participants · Start Dec 7, 2022 · Primary completion Oct 8, 2023
Drug: 15 mg ADC189; 45 mg ADC189 and 1 more · For: Safety Issues; Effect of Drug
Sites: Shanghai, China
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With InfluenzaPivotal-lookingCompleted
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06507813 · 190 participants · Start Aug 19, 2024 · Primary completion Jan 27, 2025
Drug: ADC189 tablets; Baloxavir Marboxil tablets and 6 more · For: Influenza Type A; Influenza Type B
Sites: Beijing, China
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06428903 · 48 participants · Start Mar 12, 2024 · Primary completion Sep 22, 2024
Drug: ADC189 tablet; ADC189 granules and 1 more · For: Healthy Volunteer
Sites: Jinan, China
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06485401 · 16 participants · Start Mar 14, 2024 · Primary completion Jun 21, 2024
Drug: ADC189 · For: Influenza Type A; Influenza Type B
Sites: Suzhou, China
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06589635 · 16 participants · Start Jul 16, 2024 · Primary completion Sep 11, 2024
Drug: ADC-189 and Itraconazole · For: Healthy Adults
Sites: Bengbu, China
Jiaxing AnDiCon Biotech Co.,LtdIndustry
NCT06360796 · 6 participants · Start Nov 24, 2023 · Primary completion Feb 20, 2024
Drug: [(14)C]ADC189 · For: Pharmacokinetics; Metabolism
Sites: Bengbu, China
Newest research
PubMed records naming it or its code names, newest first.
- Single-Dose Anti-Influenza Therapies: Current Progress and Future Perspectives.
Chen B, Li M, Zhang N, et al. · Clin Drug Investig 2026
- Pharmacokinetics, mass balance and metabolism of [14C] ADC189, a novel inhibitor of the polymerase acidic protein, in humans.
Wang Z, Ding J, Xu Y, et al. · Eur J Pharm Sci 2026
- Oral ADC189 for adults and adolescents with uncomplicated influenza.
Zhao J, Sheng G, Lyu Y, et al. · J Infect 2025
- Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial.
Wei J, Deng Y, Zhu X, et al. · Front Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.